| 前收市價 | 6.50 |
| 開市 | 6.50 |
| 買盤 | 0.00 |
| 賣出價 | 0.00 |
| 拍板 | 135.00 |
| 到期日 | 2026-01-16 |
| 今日波幅 | 6.50 - 6.50 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 749 |
ZacksStudy: Merck and Daiichi's Lung Cancer Treatment Shows Promise
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.
BenzingaMerck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). The approval marks the first indication for Keytruda in MPM in the U.S. Also Read: Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study. MPM is a rare, aggressive cancer that forms in the lining of
BenzingaMerck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from the HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who received prior EGFR tyrosine kinase inhibitor (TKI) treatment. The study met its primary endpoint of progression-free survival (PFS), with patritumab deruxtecan demonstrating a statistically significant improvement versus platinum plus pemetrexed induction chemotherapy followed
